Pub Date : 2023-12-15DOI: 10.1097/ot9.0000000000000014
Y. Qin, Wen-Feng Zeng, Wei Liang
Cancer treatment is a multifaceted challenge, and therapeutic vaccines have emerged as a promising approach. The micellar preparation efficiently encapsulates antigen polypeptides and enhances antigen presentation through the major histocompatibility class I pathway, promoting cytotoxic T lymphocyte immune responses. Moreover, it enables codelivery of both antigen and adjuvant to the same target antigen-presenting cells. Combining the micellar vaccine with traditional cancer treatments (such as chemotherapy, radiotherapy, and surgery) has demonstrated improved efficacy in murine tumor models. Overall, the polyethylene glycol–phosphatidylethanolamine micelle-based vaccine presents a promising platform for cancer therapeutic vaccines. By leveraging the strengths of various treatment modalities, this innovative vaccine approach holds the potential to revolutionize cancer therapy and bring new possibilities for cancer patients.
癌症治疗是一项多方面的挑战，而治疗性疫苗已成为一种前景广阔的方法。胶束制剂能有效封装抗原多肽，通过主要组织相容性 I 类途径增强抗原呈递，促进细胞毒性 T 淋巴细胞免疫反应。此外，它还能将抗原和佐剂共同输送到同一目标抗原呈递细胞。在小鼠肿瘤模型中，将胶束疫苗与传统癌症治疗方法（如化疗、放疗和手术）结合使用可提高疗效。总之，聚乙二醇磷脂酰乙醇胺胶束疫苗为癌症治疗疫苗提供了一个前景广阔的平台。通过利用各种治疗方法的优势，这种创新疫苗方法有望彻底改变癌症疗法，为癌症患者带来新的可能。
{"title":"Development of therapeutic cancer vaccines using nanomicellar preparations","authors":"Y. Qin, Wen-Feng Zeng, Wei Liang","doi":"10.1097/ot9.0000000000000014","DOIUrl":"https://doi.org/10.1097/ot9.0000000000000014","url":null,"abstract":"\u0000 Cancer treatment is a multifaceted challenge, and therapeutic vaccines have emerged as a promising approach. The micellar preparation efficiently encapsulates antigen polypeptides and enhances antigen presentation through the major histocompatibility class I pathway, promoting cytotoxic T lymphocyte immune responses. Moreover, it enables codelivery of both antigen and adjuvant to the same target antigen-presenting cells. Combining the micellar vaccine with traditional cancer treatments (such as chemotherapy, radiotherapy, and surgery) has demonstrated improved efficacy in murine tumor models. Overall, the polyethylene glycol–phosphatidylethanolamine micelle-based vaccine presents a promising platform for cancer therapeutic vaccines. By leveraging the strengths of various treatment modalities, this innovative vaccine approach holds the potential to revolutionize cancer therapy and bring new possibilities for cancer patients.","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"340 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138996553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-15DOI: 10.1097/ot9.0000000000000019
Yu Du, Xue Bai, Lu Si
Mucosal melanoma (MM) is extremely rare in Caucasians, whereas it is the second predominant melanoma subtype in Asian and other non-Caucasian populations. Distinct from cutaneous melanoma in terms of epidemiology, biology, and molecular characteristics, MM is characterized by more aggressive biological behavior, lower mutational burden, more chromosomal structure variants, and poorer prognosis. Because of the rarity of MM, its biological features are not fully understood, and potential novel therapies are less well depicted. Whereas immunotherapy has shown encouraging efficacy for cutaneous melanoma, its efficacy in MM is unclear due to limited sample sizes in clinical trials. Thus, in this review, we describe the epidemiological, clinical, and molecular features of MM and summarize the efficacies of different immunotherapies for MM, including immune checkpoint inhibitors, vaccines, oncolytic virus therapy, adoptive T-cell therapy, and various combination therapies.
粘膜黑色素瘤（MM）在白种人中极为罕见，而在亚洲人和其他非白种人中则是第二主要的黑色素瘤亚型。粘膜黑色素瘤在流行病学、生物学和分子特征方面均有别于皮肤黑色素瘤，其特点是生物学行为更具侵袭性、突变负荷较低、染色体结构变异较多以及预后较差。由于 MM 的罕见性，人们对其生物学特征尚不完全了解，对潜在的新型疗法的描述也较少。免疫疗法对皮肤黑色素瘤的疗效令人鼓舞，但由于临床试验的样本量有限，其对 MM 的疗效尚不明确。因此，在这篇综述中，我们描述了 MM 的流行病学、临床和分子特征，并总结了不同免疫疗法对 MM 的疗效，包括免疫检查点抑制剂、疫苗、溶瘤病毒疗法、收养 T 细胞疗法和各种联合疗法。
{"title":"Immunotherapy for mucosal melanoma","authors":"Yu Du, Xue Bai, Lu Si","doi":"10.1097/ot9.0000000000000019","DOIUrl":"https://doi.org/10.1097/ot9.0000000000000019","url":null,"abstract":"\u0000 Mucosal melanoma (MM) is extremely rare in Caucasians, whereas it is the second predominant melanoma subtype in Asian and other non-Caucasian populations. Distinct from cutaneous melanoma in terms of epidemiology, biology, and molecular characteristics, MM is characterized by more aggressive biological behavior, lower mutational burden, more chromosomal structure variants, and poorer prognosis. Because of the rarity of MM, its biological features are not fully understood, and potential novel therapies are less well depicted. Whereas immunotherapy has shown encouraging efficacy for cutaneous melanoma, its efficacy in MM is unclear due to limited sample sizes in clinical trials. Thus, in this review, we describe the epidemiological, clinical, and molecular features of MM and summarize the efficacies of different immunotherapies for MM, including immune checkpoint inhibitors, vaccines, oncolytic virus therapy, adoptive T-cell therapy, and various combination therapies.","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"131 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138998323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-15DOI: 10.1097/ot9.0000000000000015
Amir M. Parray, Anoop Singh, Vikram Chaudhari, Avinash Supe
Pancreatic cystic neoplasms present a complex diagnostic scenario encompassing low- and high-grade malignancies. Their prevalence varies widely, notably increasing with age, reaching 75% in individuals older than 80 years. Accurate diagnosis is crucial, as errors occur in approximately one-third of resected cysts discovered incidentally. Various imaging modalities such as computed tomography, magnetic resonance imaging, and endoscopic techniques are available to address this challenge. However, risk stratification remains problematic, with guideline inconsistencies and diagnostic accuracy varying according to cyst type. This review proposed a stepwise management approach, considering patient factors, imaging results, and specific features. This patient-centered model offers a structured framework for optimizing the care of individuals with pancreatic cystic neoplasms.
{"title":"Pancreatic cystic neoplasms: a comprehensive approach to diagnosis and management","authors":"Amir M. Parray, Anoop Singh, Vikram Chaudhari, Avinash Supe","doi":"10.1097/ot9.0000000000000015","DOIUrl":"https://doi.org/10.1097/ot9.0000000000000015","url":null,"abstract":"\u0000 Pancreatic cystic neoplasms present a complex diagnostic scenario encompassing low- and high-grade malignancies. Their prevalence varies widely, notably increasing with age, reaching 75% in individuals older than 80 years. Accurate diagnosis is crucial, as errors occur in approximately one-third of resected cysts discovered incidentally. Various imaging modalities such as computed tomography, magnetic resonance imaging, and endoscopic techniques are available to address this challenge. However, risk stratification remains problematic, with guideline inconsistencies and diagnostic accuracy varying according to cyst type. This review proposed a stepwise management approach, considering patient factors, imaging results, and specific features. This patient-centered model offers a structured framework for optimizing the care of individuals with pancreatic cystic neoplasms.","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"90 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138997622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of the study was to investigate effective diagnostic molecular markers and the specific mechanisms of metastatic pheochromocytomas and paragangliomas (PPGLs). Data were collected from GEO datasets GSE67066 and GSE60458. The R software and various packages were utilized for the analysis of differentially expressed genes, Gene Ontology analysis, Kyoto Encyclopedia of Genes and Genomes analysis, receiver operating characteristic curve assessment, logistic model construction, and correlation analysis. The NetworkAnalyst tool was used to analyze gene-miRNA interactions and signaling networks. In addition, the TIMER database was used to estimate the immune scores. A total of 203 and 499 differentially expressed genes were identified in GSE67066 and GSE60458, respectively. These genes are implicated in cytokine and cytokine receptor interactions, extracellular matrix–receptor interactions, and platelet activation signaling pathways. Notably, MAMLD1, UST, MATN2, LPL, TWIST1, SFRP4, FRMD6, RBM24, PRIMA1, LYPD1, KCND2, CAMK2N1, SPOCK3, and ALPK3 were identified as the key genes. Among them, MATN2 and TWIST1 were found to be coexpressed with epithelial-mesenchymal transition–linked markers, whereas KCND2 and LPL exhibited associations with immune checkpoint expression and immune cell infiltration. Eight miRNAs were identified as potential regulators of key gene expression, and it was noted that TWIST1 might be regulated by SUZ12. Notably, the area under the curve of the 4-gene model for distinguishing between malignant and benign groups was calculated to be 0.918. The combined gene and mRNA expression model enhances the diagnostic accuracy of assessing PPGL metastatic potential. These findings suggest that multiple genes may play a role in the metastasis of PPGLs through the epithelial-mesenchymal transition and may influence the immune microenvironment.
{"title":"Utilizing bioinformatics for integrated analysis of multiple genes in the diagnosis and pathogenesis of metastatic pheochromocytoma and paraganglioma","authors":"Chun-Lei Zhang, Rui Wang, Fo-Rong Li, De-Hui Chang","doi":"10.1097/ot9.0000000000000023","DOIUrl":"https://doi.org/10.1097/ot9.0000000000000023","url":null,"abstract":"\u0000 \u0000 \u0000 The aim of the study was to investigate effective diagnostic molecular markers and the specific mechanisms of metastatic pheochromocytomas and paragangliomas (PPGLs).\u0000 \u0000 \u0000 \u0000 Data were collected from GEO datasets GSE67066 and GSE60458. The R software and various packages were utilized for the analysis of differentially expressed genes, Gene Ontology analysis, Kyoto Encyclopedia of Genes and Genomes analysis, receiver operating characteristic curve assessment, logistic model construction, and correlation analysis. The NetworkAnalyst tool was used to analyze gene-miRNA interactions and signaling networks. In addition, the TIMER database was used to estimate the immune scores.\u0000 \u0000 \u0000 \u0000 A total of 203 and 499 differentially expressed genes were identified in GSE67066 and GSE60458, respectively. These genes are implicated in cytokine and cytokine receptor interactions, extracellular matrix–receptor interactions, and platelet activation signaling pathways. Notably, MAMLD1, UST, MATN2, LPL, TWIST1, SFRP4, FRMD6, RBM24, PRIMA1, LYPD1, KCND2, CAMK2N1, SPOCK3, and ALPK3 were identified as the key genes. Among them, MATN2 and TWIST1 were found to be coexpressed with epithelial-mesenchymal transition–linked markers, whereas KCND2 and LPL exhibited associations with immune checkpoint expression and immune cell infiltration. Eight miRNAs were identified as potential regulators of key gene expression, and it was noted that TWIST1 might be regulated by SUZ12. Notably, the area under the curve of the 4-gene model for distinguishing between malignant and benign groups was calculated to be 0.918.\u0000 \u0000 \u0000 \u0000 The combined gene and mRNA expression model enhances the diagnostic accuracy of assessing PPGL metastatic potential. These findings suggest that multiple genes may play a role in the metastasis of PPGLs through the epithelial-mesenchymal transition and may influence the immune microenvironment.\u0000","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"189 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138998199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-15DOI: 10.1097/ot9.0000000000000016
In his 50 years of practice, he has performed more than 20,000 hepatopancreatobiliary surgeries, being the first one to propose the concept of the “auxiliary partial orthotopic liver transplantation” internationally. Furthermore, he developed the “Chen's inserting biliary-enteric anastomosis and pancreato-enteric anastomosis,” “Chen's hepatic vascular occlusion,” “Chen's liver double-hanging maneuver,” and “Chen's hepatic vascular occlusion without liver portal dissection.” He also popularized these theories and techniques both in China and worldwide. His name is Xiao-Ping Chen, an academician of the Chinese Academy of Sciences and honorary president of the Tongji Medical College of Huazhong University of Science and Technology.
{"title":"Xiao-Ping Chen: the “Master of the Scalpel” who saves lives by entering the forbidden territory of hepatopancreatobiliary surgery","authors":"","doi":"10.1097/ot9.0000000000000016","DOIUrl":"https://doi.org/10.1097/ot9.0000000000000016","url":null,"abstract":"\u0000 In his 50 years of practice, he has performed more than 20,000 hepatopancreatobiliary surgeries, being the first one to propose the concept of the “auxiliary partial orthotopic liver transplantation” internationally. Furthermore, he developed the “Chen's inserting biliary-enteric anastomosis and pancreato-enteric anastomosis,” “Chen's hepatic vascular occlusion,” “Chen's liver double-hanging maneuver,” and “Chen's hepatic vascular occlusion without liver portal dissection.” He also popularized these theories and techniques both in China and worldwide. His name is Xiao-Ping Chen, an academician of the Chinese Academy of Sciences and honorary president of the Tongji Medical College of Huazhong University of Science and Technology.","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"22 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139000618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-15DOI: 10.1097/ot9.0000000000000017
Yang Yang, Zhi-Gang Liu, Yan-Qi Yang, Zhi-Gang Zhang, Xiao-Li Wang, Yu-Long Li, Rui-Fang Sun
There is growing evidence that the gene named tumor necrosis factor α–induced protein 6 (TNFAIP6) has an important role in various tumors. However, a systematic pan-cancer analysis of TNFAIP6 is lacking. Here we aimed to analyze the expression of TNFAIP6 across multiple cancers and verify its expression during the progression of colon cancer. We performed a comprehensive bioinformatics analysis to examine the expression of TNFAIP6 across 27 tumor types. GEPIA2 was used to evaluate the effect of TNFAIP6 on clinical cancer prognosis. cBioportal was used to assess TNFAIP6 mutations. The correlation between TNFAIP6 and cancer immune infiltrates was explored using TIMER2.0. The CancerSEA database was used to perform functional analysis of TNFAIP6. Metascape was used to identify TNFAIP6-related gene enrichment pathways. Immunohistochemistry was performed to detect TNFAIP6 protein expression in the colon cancer. In addition, the Comparative Toxicogenomics Database was searched for known and possible antitumor drugs that may be associated with TNFAIP6. We found that, in most of the cancers included in this analysis, TNFAIP6 was highly expressed, and there is a distinct relationship between TNFAIP6 expression and cancer prognosis. TNFAIP6 expression is associated with cancer-associated fibroblasts, neutrophils, and endothelial cells. TNFAIP6 and similar genes may also be involved in the PID_VEGF_VEGFR_ pathway. Immunohistochemistry revealed an increasing trend of TNFAIP6 protein expression in normal, adenoma, and colon cancer tissues. Several known and possible antitumor drugs that may be associated with TNFAIP6 were identified in the Comparative Toxicogenomics Database. These results suggest that a number of drugs may target TNFAIP6 during cancer treatment, including cisplatin, irinotecan, resveratrol, U 0126, NSC689534, genistein, NSC668394, oxaliplatin, plerixafor, topotecan, vincristine, flutamide, doxorubicin, MRK 003, folic acid, demecolcine, tunicamycin, zoledronic acid, and schizandrin B. TNFAIP6 may function as an oncogene in certain cancers. Furthermore, this study provides evidence that TNFAIP6 is an important factor in colon cancer progression.
{"title":"Role of tumor necrosis factor alpha-induced protein 6 (TNFAIP6) in tumors: A pan-cancer analysis","authors":"Yang Yang, Zhi-Gang Liu, Yan-Qi Yang, Zhi-Gang Zhang, Xiao-Li Wang, Yu-Long Li, Rui-Fang Sun","doi":"10.1097/ot9.0000000000000017","DOIUrl":"https://doi.org/10.1097/ot9.0000000000000017","url":null,"abstract":"\u0000 \u0000 \u0000 There is growing evidence that the gene named tumor necrosis factor α–induced protein 6 (TNFAIP6) has an important role in various tumors. However, a systematic pan-cancer analysis of TNFAIP6 is lacking. Here we aimed to analyze the expression of TNFAIP6 across multiple cancers and verify its expression during the progression of colon cancer.\u0000 \u0000 \u0000 \u0000 We performed a comprehensive bioinformatics analysis to examine the expression of TNFAIP6 across 27 tumor types. GEPIA2 was used to evaluate the effect of TNFAIP6 on clinical cancer prognosis. cBioportal was used to assess TNFAIP6 mutations. The correlation between TNFAIP6 and cancer immune infiltrates was explored using TIMER2.0. The CancerSEA database was used to perform functional analysis of TNFAIP6. Metascape was used to identify TNFAIP6-related gene enrichment pathways. Immunohistochemistry was performed to detect TNFAIP6 protein expression in the colon cancer. In addition, the Comparative Toxicogenomics Database was searched for known and possible antitumor drugs that may be associated with TNFAIP6.\u0000 \u0000 \u0000 \u0000 We found that, in most of the cancers included in this analysis, TNFAIP6 was highly expressed, and there is a distinct relationship between TNFAIP6 expression and cancer prognosis. TNFAIP6 expression is associated with cancer-associated fibroblasts, neutrophils, and endothelial cells. TNFAIP6 and similar genes may also be involved in the PID_VEGF_VEGFR_ pathway. Immunohistochemistry revealed an increasing trend of TNFAIP6 protein expression in normal, adenoma, and colon cancer tissues. Several known and possible antitumor drugs that may be associated with TNFAIP6 were identified in the Comparative Toxicogenomics Database. These results suggest that a number of drugs may target TNFAIP6 during cancer treatment, including cisplatin, irinotecan, resveratrol, U 0126, NSC689534, genistein, NSC668394, oxaliplatin, plerixafor, topotecan, vincristine, flutamide, doxorubicin, MRK 003, folic acid, demecolcine, tunicamycin, zoledronic acid, and schizandrin B.\u0000 \u0000 \u0000 \u0000 \u0000 TNFAIP6 may function as an oncogene in certain cancers. Furthermore, this study provides evidence that TNFAIP6 is an important factor in colon cancer progression.\u0000","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"47 27","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138996032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.1097/ot9.0000000000000022
Augmented- and mixed-reality technologies have pioneered the realization of real-time fusion and interactive projection for laparoscopic surgeries. Indocyanine green fluorescence imaging technology has enabled anatomical, functional, and radical hepatectomy through tumor identification and localization of target hepatic segments, driving a transformative shift in the management of hepatic surgical diseases, moving away from traditional, empirical diagnostic and treatment approaches toward digital, intelligent ones. The Hepatic Surgery Group of the Surgery Branch of the Chinese Medical Association, Digital Medicine Branch of the Chinese Medical Association, Digital Intelligent Surgery Committee of the Chinese Society of Research Hospitals, and Liver Cancer Committee of the Chinese Medical Doctor Association organized the relevant experts in China to formulate this consensus. This consensus provides a comprehensive outline of the principles, advantages, processes, and key considerations associated with the application of augmented reality and mixed-reality technology combined with indocyanine green fluorescence imaging technology for hepatic segmental and subsegmental resection. The purpose is to streamline and standardize the application of these technologies.
{"title":"Chinese expert consensus on laparoscopic hepatic segmentectomy and subsegmentectomy navigated by augmented- and mixed-reality technology combined with indocyanine green fluorescence imaging","authors":"","doi":"10.1097/ot9.0000000000000022","DOIUrl":"https://doi.org/10.1097/ot9.0000000000000022","url":null,"abstract":"Augmented- and mixed-reality technologies have pioneered the realization of real-time fusion and interactive projection for laparoscopic surgeries. Indocyanine green fluorescence imaging technology has enabled anatomical, functional, and radical hepatectomy through tumor identification and localization of target hepatic segments, driving a transformative shift in the management of hepatic surgical diseases, moving away from traditional, empirical diagnostic and treatment approaches toward digital, intelligent ones. The Hepatic Surgery Group of the Surgery Branch of the Chinese Medical Association, Digital Medicine Branch of the Chinese Medical Association, Digital Intelligent Surgery Committee of the Chinese Society of Research Hospitals, and Liver Cancer Committee of the Chinese Medical Doctor Association organized the relevant experts in China to formulate this consensus. This consensus provides a comprehensive outline of the principles, advantages, processes, and key considerations associated with the application of augmented reality and mixed-reality technology combined with indocyanine green fluorescence imaging technology for hepatic segmental and subsegmental resection. The purpose is to streamline and standardize the application of these technologies.","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139194409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-15DOI: 10.1097/ot9.0000000000000020
Shuai Xiang, Xiao-Ping Chen
Hilar cholangiocarcinoma is a malignant tumor that originates from the left and right hepatic ducts and their confluence. It is highly malignant and associated with a poor prognosis. Surgical resection is the only available curative treatment option. A scientific classification system can aid in the preoperative assessment of resectability and guide the development of appropriate surgical strategies. Several classification systems are available, with the Bismuth-Corlette (BC) classification being the earliest and most widely used. Similar to many other classifications, the BC classification relies on the secondary branching of the bile ducts as an important anatomical landmark, making it unsuitable for cases with variations in the bile duct anatomy. With advances in understanding the hepatic plate and anatomical structures at the hilum, the secondary bile ducts are no longer considered important anatomical landmarks. Therefore, modifications to the BC classification are needed to align with modern anatomical improvements and advancements in surgical techniques. Herein, we propose a modification to the BC classification. In this new system, the boundary of the hilar plate is considered as limit of the proximal ductal margin and used as an anatomical landmark, rather than the concept of “secondary bile ducts” in the BC classification.
肝门部胆管癌是一种起源于左右肝管及其汇合处的恶性肿瘤。这种肿瘤恶性程度高，预后较差。手术切除是唯一可治愈的治疗方案。科学的分类系统有助于术前评估可切除性，并指导制定适当的手术策略。目前有几种分类系统，其中铋-科莱特（Bismuth-Corlette，BC）分类是使用最早、最广泛的一种。与许多其他分类方法类似，BC 分类法依赖胆管的二级分支作为重要的解剖标志，因此不适合胆管解剖结构存在变异的病例。随着对肝板和肝门解剖结构认识的进步，二级胆管不再被视为重要的解剖标志。因此，需要对 BC 分类进行修改，以适应现代解剖学的改进和手术技术的进步。在此，我们提出了 BC 分类的修改方案。在这一新系统中，肝板边界被视为近端胆管边缘的界限，并被用作解剖标志，而不是 BC 分类中的 "次级胆管 "概念。
{"title":"Proposal of a modified classification for hilar cholangiocarcinoma","authors":"Shuai Xiang, Xiao-Ping Chen","doi":"10.1097/ot9.0000000000000020","DOIUrl":"https://doi.org/10.1097/ot9.0000000000000020","url":null,"abstract":"Hilar cholangiocarcinoma is a malignant tumor that originates from the left and right hepatic ducts and their confluence. It is highly malignant and associated with a poor prognosis. Surgical resection is the only available curative treatment option. A scientific classification system can aid in the preoperative assessment of resectability and guide the development of appropriate surgical strategies. Several classification systems are available, with the Bismuth-Corlette (BC) classification being the earliest and most widely used. Similar to many other classifications, the BC classification relies on the secondary branching of the bile ducts as an important anatomical landmark, making it unsuitable for cases with variations in the bile duct anatomy. With advances in understanding the hepatic plate and anatomical structures at the hilum, the secondary bile ducts are no longer considered important anatomical landmarks. Therefore, modifications to the BC classification are needed to align with modern anatomical improvements and advancements in surgical techniques. Herein, we propose a modification to the BC classification. In this new system, the boundary of the hilar plate is considered as limit of the proximal ductal margin and used as an anatomical landmark, rather than the concept of “secondary bile ducts” in the BC classification.","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139274980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-15DOI: 10.1097/ot9.0000000000000018
Xiao-Lan Jian, Puhua Zeng, Kexiong Li, Wei Peng
To investigate the role of fibroblast growth factor 2 (FGF2) in chemotherapy resistance of colon cancer. An HCT116/5-fluorouracil (5-FU)–resistant cell line was established, and FGF2 levels were detected in a sensitive cell group (HCT116) and a resistant cell group (HCT1116-R) using different methods. Fibroblast growth factor 2 levels in the medium were determined by enzyme-linked immunoassay. The protein expressions of FGF2, fibroblast growth factor receptor 1 (FGFR1), and phospho-FGFR1 were assessed by Western blotting, and FGF2 mRNA levels were detected by quantitative real-time polymerase chain reaction. Fibroblast growth factor 2 recombinant protein was added to sensitive cells, and FGFR inhibitor AZD4547 was added to resistant cells, and the cell survival rate was determined using the cell counting kit-8 method and the protein expressions of PI3K (phosphatidylinositol 3 kinase), p-PI3K (phospho-PI3K), Akt (protein kinase B), p-Akt (phospho-Akt), mammalian target of rapamycin (mTOR), p-mTOR (phospho-mTOR), Bad (Bcl-xL/Bcl-2–associated death promoter), NF-κB (nuclear factor κB), GSK-3 (glycogen synthase kinase-3), FKHR (forkhead box protein O1), and PTEN (phosphatase and tensin homolog deleted on chromosome ten) were detected by Western blotting. Fibroblast growth factor 2 protein and mRNA expression levels in the HCT116-R group were significantly higher than those in the HCT116 group. Fibroblast growth factor 2 increased the survival rate of HCT116 cells; improved tolerance to 5-FU; upregulated p-PI3K, p-Akt, and p-mTOR; and downregulated Bad. The FGFR inhibitor AZD4547 decreased cell survival rate and tolerance to 5-FU; downregulated p-PI3K, p-Akt, and p-mTOR expression; and upregulated Bad. Fibroblast growth factor 2 promotes chemotherapy tolerance in colon cancer cells by activating the Akt/mTOR and Akt/Bad signaling pathways downstream of PI3K.
{"title":"FGF2 promotes the chemotherapy resistance in colon cancer cells through activating PI3K/Akt signaling pathway","authors":"Xiao-Lan Jian, Puhua Zeng, Kexiong Li, Wei Peng","doi":"10.1097/ot9.0000000000000018","DOIUrl":"https://doi.org/10.1097/ot9.0000000000000018","url":null,"abstract":"To investigate the role of fibroblast growth factor 2 (FGF2) in chemotherapy resistance of colon cancer. An HCT116/5-fluorouracil (5-FU)–resistant cell line was established, and FGF2 levels were detected in a sensitive cell group (HCT116) and a resistant cell group (HCT1116-R) using different methods. Fibroblast growth factor 2 levels in the medium were determined by enzyme-linked immunoassay. The protein expressions of FGF2, fibroblast growth factor receptor 1 (FGFR1), and phospho-FGFR1 were assessed by Western blotting, and FGF2 mRNA levels were detected by quantitative real-time polymerase chain reaction. Fibroblast growth factor 2 recombinant protein was added to sensitive cells, and FGFR inhibitor AZD4547 was added to resistant cells, and the cell survival rate was determined using the cell counting kit-8 method and the protein expressions of PI3K (phosphatidylinositol 3 kinase), p-PI3K (phospho-PI3K), Akt (protein kinase B), p-Akt (phospho-Akt), mammalian target of rapamycin (mTOR), p-mTOR (phospho-mTOR), Bad (Bcl-xL/Bcl-2–associated death promoter), NF-κB (nuclear factor κB), GSK-3 (glycogen synthase kinase-3), FKHR (forkhead box protein O1), and PTEN (phosphatase and tensin homolog deleted on chromosome ten) were detected by Western blotting. Fibroblast growth factor 2 protein and mRNA expression levels in the HCT116-R group were significantly higher than those in the HCT116 group. Fibroblast growth factor 2 increased the survival rate of HCT116 cells; improved tolerance to 5-FU; upregulated p-PI3K, p-Akt, and p-mTOR; and downregulated Bad. The FGFR inhibitor AZD4547 decreased cell survival rate and tolerance to 5-FU; downregulated p-PI3K, p-Akt, and p-mTOR expression; and upregulated Bad. Fibroblast growth factor 2 promotes chemotherapy tolerance in colon cancer cells by activating the Akt/mTOR and Akt/Bad signaling pathways downstream of PI3K.","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139273612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.1007/s10330-022-0599-9
Xiaokun Wang, Min Qi, Xuelin Zhu, Zhengtong Zhao, Yufeng Cao, D. Xing, Fuman Wang, Gaoyang Lin
{"title":"EZH2 is a biomarker associated with lung cancer diagnosis and immune infiltrates without prognostic specificity: a study based on the cancer genome atlas data","authors":"Xiaokun Wang, Min Qi, Xuelin Zhu, Zhengtong Zhao, Yufeng Cao, D. Xing, Fuman Wang, Gaoyang Lin","doi":"10.1007/s10330-022-0599-9","DOIUrl":"https://doi.org/10.1007/s10330-022-0599-9","url":null,"abstract":"","PeriodicalId":345149,"journal":{"name":"Oncology and Translational Medicine","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114259843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：